natgillin/translations-raw huggingface dataset:
The kit of claim 13, wherein the antibody-drug conjugate has the following formula: wherein Ab is selected from the group consisting of: 
Konjugat lijeka i antitijela iz patentnog zahtjeva 14 naznačeno time da ima sljedeću formulu: gdje je Ab odabran iz skupine koju čine:
Valve according to claim 4, wherein said two swing elements are of the same shape and size. 
Ventil (10) u skladu s patentnim zahtjevom 3, pri čemu su navedena dva zakretna elementa (18, 20) istoga oblika i veličine.
is (C2-C6)alkenyl, aryl, aryl-S—, heteroaryl or aryl(C1-C6)alkyl, wherein said aryl or heteroaryl as such or as part of another group is substituted with 1 or 2 substituent(s) R6; 
R, je (C2-Cg)alkenil, aril, aril-S-, heteroaril ili ari(C,-Cs)alkil, pri čemu je rečeni aril ili heteroaril kao takav ili kao dio druge skupine supstituiran s 1 ili 2 supstituenta Rg;
the fast-acting insulin analog and the hyaluronan degrading enzyme are in the same or different reservoirs, wherein the closed loop system closely mimics the endogenous insulin response in a non-diabetic subject. 
HR P20150313 T1 brzo djelujući analog inzulina 1 enzim koji razgrađuje hijaluronan su u istom ili različitim rezervoarima, pri čemu sustav sa zatvorenim krugom vrlo dobro podražava endogeno poslije-obroka oslobađanje inzulina kod nedijabetičkog subjekta
wherein RA is a halogen atom, a C1-6 alkyl group or a C1-6 alkoxy group; RB is a phenyl group optionally substituted by a halogen atom, a cyano group, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, a halo-C1-6 alkoxy group, or a mono- or di-C1-6 alkylamino group; or a heterocyclyl group optionally substituted by a halogen atom, a cyano group, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group, a halo-C1-6 alkoxy group, or a mono- or di-C1-6 alkylamino group; and Rc is hydrogen atom; or RB and RC taken together are a fused benzene ring which may be substituted by a halogen atom, a C1-6 alkyl group, a halo-C1-6 alkyl group, a C1-6 alkoxy group or a halo-C1-6 alkoxy group or a pharmaceutically acceptable salt thereof; 
a je atom halogena, C1-6 alkilna skupina ili C1-6 alkoksi skupina; a i R3a su atomi vodika; a je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom, halogen-C1-6 alkilnom skupinom, C1-6 alkoksi skupinom, halogen-C1-6 alkoksi skupinom, te mono- ili di-C1-6 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1-6 alkilnom skupinom ili C1-6 alkoksi skupinom; i Y je -CH2-.
It is further disclosed that the soaked ligno-cellulosic biomass stream before separation step e) has a free liquid and the percent amount of the free liquid may less than a value selected from the group consisting of 20%, 10% and 5% by weight of the solid ligno-cellulosic biomass. 
Proces iz bilo kojeg od patentnih zahtjeva 1 do 6, gdje struja natopljene ligno-celulozne biomase prije koraka odvajanja e) ima slobodnu tekućinu i postotna količina slobodne tekućine je manja od vrijednosti odabrane iz grupe koja se sastoji od 20%, 10% i 5% po masi struje natopljene ligno-celulozne biomase.
Such polynucleotides may be administered or used in the prevention or treatment of allergy to cats by tolerisation. 
Sastav za uporabu u prevenciji ili liječenju alergije na grinje iz kućne prašine po toleranciji, naznačen time, što sadrži:
Transport pallet, module and folding sheets for same, and method for producing a transport pallet 
TRANSPORTNA PALETA I POSTUPAK ZA PROIZVODNJU TRANSPORTNE PALETE
The process of paragraph 1, wherein said second solvent is selected from the group consisting of xylene, N-methylpyrrolidinone, dimethyl acetamide, DMSO, and mixtures of 2 or more thereof. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeno drugo otapalo se bira iz skupine koju čine ksilen, V-metilpirolidinon, dimetilacetamid, DMSO, te smjese 2 ili više njih.
or or a pharmaceutically acceptable salt or acid addition salt, a racemic mixture, or its corresponding enantiomer and/or optical isomer and/or stereoisomer thereof. 
IE ili ili njegova farmaceutski prihvatljiva sol ili kiselinska adicijska sol, njegova racemična smjesa ili njezini odgovarajući enantiomer i/ili optički izomer i/ili stereoizomer.
at least one source of citrate; wherein the composition has a bulk density of 035-0.75 g/cm3 and comprises from 8% to 15% (wt/wt) magnesium and from 7.5% to 16% (wt/wt) potassium and 75% to 80% citrate on dry weight basis. 
(ili) najmanje jedan izvor citrata; pri čemu sastav ima ukupnu gustoću od 0,35-0,75 g/em? i obuhvaća od 8% do 15% (wt/wt) magnezija i od 7,5% do 16% (wt/'wt) kalija 1 75% do 80% citrata u masi suhe osnove.
Thus, the inlet valve 7 is open in this first position so that the liquid 4 can fill the metering chamber 6 due to the pressure in the container 3 . 
Stoga, dakle, ulazni ventil 7 u tom prvom položaju je otvoren tako da tekućina 4 može ispuniti omjernu komoru 6 zbog pritiska u spremniku 3.
Preferably, the signal received from the tag is an optical signal. 
Sustav prema zahtjevu 3, naznačen time što je signal koji se prima od oznake (3) optički signal.
The pair of primers can be referred to as a first primer consisting of at least about 15 to about 50 contiguous nucleotides from the corn genome portion of SEQ ID NO:3 and a second primer consisting of at least about 15 to about 50 contiguous nucleotides complementary to the heterologous insert DNA portion of SEQ ID NO:5. 
(i) se prva navedena DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida komplementarnih sa heterolognim dijelom unutar DNA SEQ ID NO: 5, i pri čemu se navedena druga DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida iz dijela SEQ ID NO: 3 kukuruznog genoma; ili
In case of strong corrugation, or "buckling," said veneer is additionally subjected to a pressing step. 
U slučaju jake valovitosti ili "izvijenosti" navedeni furnir se dodatno podvrgava fazi prešanja.
Process according to any one of the preceding claims, characterized in that the glued surfaces of the board-like, plane pieces of wood (10) are planned prior to the adhesion, particularly by using a rotary machining tool. 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, što su površine koje se lijepe, ravnih komada od drva koje ima oblik ploče (10), izravnane prije lijepljenja, naročito upotrebom rotacijskog alatnog stroja.
The overall conclusion of the statistical evaluation was that "there is a tendency to significance: sugar-free cakes are preferred over sugar-containing cakes". 
Ukupni je zaključak, utemeljen na statističkoj analizi, bio da Â«postoji tendencija k značajnosti: kolačima bez šećera daje se prednost pred kolačima pripravljenima sa šećerom».
The device according to one of claims 1 to 4, wherein Localized Virtual Resource Blocks (LVRBs), which are mapped to PRBs, are allocated to the device by units of RBGs. 
Integrirani krug sukladno jednom od zahtjeva 1 do 9, naznačen time da su u drugoj dodjeli, lokaliziram virtualni blokovi resursa, LVRB-ovi, mapirani na PRB-ove, i LVRB-ovi su dodijeljeni uređaju mobilnoj stanici u jedinicama RBG-a.
The compound of Claim 1, wherein R5 is represented by the following structural formula: wherein: 
Spoj prema zahtjevu 1, pri čemu je Rs prikazan slijedećom strukturnom formulom:
2005) have demonstrated a selective deficit in this task induced by acute and sub-chronic treatment with PCP. 
2005. su pokazali selektivni deficit u tom zadatku potaknut akutnim i sub-kroničnim tretiranjem s PCP.
Total assay volume for the binding studies was 100 µl. 
Totalni volumen analize za studije vezivanja bio je 100 ul.
The hydroxyl laundry chemical injection system of claim 1, wherein the hydroxyl gas generator is configured to generate hydroxyl gas with a concentration of hydroxyl radicals of at least 900 ppm. 
Sustav za ubrizgavanje kemikalija za pranje rublja na bazi hidroksila (100) iz zahtjeva 1, naznačen time da je sustav konfiguriran da održava koncentracije hidroksil radikala unutar bubnja za pranje (1) na koncentraciji od oko 0,1 ppm do oko 0,5 ppm tijekom ciklusa pranja.
In a variation, each of steps a) and b) is carried out at a temperature in the range 200° C. to 450° C., at a pressure in the range 0.5 to 30 MPa, at an hourly space velocity in the range 0.1 to 20 h−1 and with a hydrogen/feed ratio, expressed as the volume of hydrogen measured under normal temperature and pressure conditions, per volume of liquid feed is advantageously in the range 50 L/L to 2000 L/L. 
Postupak prema jednom od zahtjeva 1 do 9, naznačen time da se svaki od koraka a) i b) provodi kod temperature u rasponu od 200*C do 450*C, kod pritiska u rasponu 0.5 do 30 MPa, kod satne prostorne brzine u rasponu 0.1 do 20 h!' i uz omjer vodik/dovod, izraženo kao volumen vodika mjereno kod uvjeta normalne temperature i tlaka, po volumenu tekuće šarže u rasponu 50 L/L, do 2000 L/L.
A method of transmitting broadcasting signal to a receiver, the method comprising: 
Metoda iz patentnog zahtjeva 1, pri čemu kodirani signalni podatak L1 nadalje obuhvaća:
Crystalline 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione having an X-ray powder diffraction pattern comprising peaks at approximately 21, 23 and 24,5 degrees 2θ. 
Kristalni 3-(4-amino-1-okso-1,3-dihidroizoindol-2-il)piperidin-2,6-dion u skladu s patentnim zahtjevom 10, naznačen time što pikovi difrakcije rendgenskih zraka na prahu su na 20,0, 24.7 i 28,6 stupnjeva 2θ.
A method for the treatment of depression, Alzheimer's disease, neuropathic pain, or Parkinson's disease, which comprises administering to a patient a therapeutically affective amount of a compound of claim 1 . 
Spoj bilo kojeg patentnog zahtjeva 1 do 7 ili farmaceutski prihvatljiva sol tog spoja za primjenu u metodi za liječenje depresije, Alzheimerove bolesti, neuropatske boli, ili Parkinsonove bolesti.
ActRIIa-hFc fusion protein was expressed in stably transfected CHO-DUKX B11 cells from a pAID4 vector (SV40 ori/enhancer, CMV promoter), using a tissue plasminogen leader sequence of SEQ ID NO:9. 
Farmaceutska smjesa iz zahtjeva 1 ili 2, naznačena time, što se ActRIla-Fc fuzijski protein rekombinantno eksprimira u CHO stanicama, uz korištenje TPA liderske sekvence SEQ ID NO: 9.
ii) processing the aqueous slurry at a temperature of at least 60°C; and iii) obtaining juice from the aqueous slurry in step (ii). 
Postupak sukladno bilo kojem od zahtjeva 1 do 3, pri čemu korak (b) obuhvaća: i) spajanje voća s vodom kako bi se dobila vodenasta kaša; ii) prerada vodenaste kaše na temperaturi od barem 60*C; 1 iii) dobivanje soka iz vodenaste kaše u koraku (ii).
The apparatus according to any one of claims 1-8, further comprising an energy source, comprising at least one of; an internal energy source, an internal energy source chargeable by wireless energy and an external energy source for transferring energy in a wireless mode. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što uređaj dodatno ima najmanje jedno od sljedećeg: unutarnji izvor napajanja (70; 470), bežični prijemnik energije (205) za neinvazivno napajanje uređaja bežičnom energijom i prijemnik energije koji prima bežičnu energiju radi punjenja unutarnjeg izvora napajanja.
The antitumor efficacy observed with the compound of Example 1 was comparable to that obtained with an equivalent dose of gemcitabine-HCl. 
Protutumorska djelotvornost opažena za spoj iz Primjera 1 usporediva je s onom dobivenom uz ekvivalentnu dozu gemcitabina-HCI.
Pressurizing the feed material to a predetermined process pressure of 150 to 400 bar; 
– stlačivanju dovodnog materijala do zadanog tlaka obrade od najmanje 150 bara (15 MPa);
The metal-chelating reagent-binding anti-p-cadherin antibody of claim 19, wherein the mole ratio of the anti-p-cadherin antibody to the metal-chelating reagent is from 1:0.5 to 1:3. 
DOTA-vezano anti-P-kadherin antitijelo u skladu s patentnim zahtjevom 12 ili 13, naznačeno time, da je molni omjer anti-P-kadherin antitijela na DOTA od I: 0,1 do 1: 4,5, poželjno 1:0,5 do 1: 3.
The anti-proliferative treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the quinazoline derivative of the invention, conventional surgery or radiotherapy or chemotherapy. 
Antiproliferativno liječenje definirano u gornjem tesktu može se primjeniti kao jedina terapija, ili može uključivati, uz derivat kinazolina iz ovog izuma, konvencionalnu kirurgiju, radioterapiju ili kemoterapiju.
Elevated triglyceride level, whether caused by genetic predisposition or by a high fat diet, is a risk factor for the development of heart disease, stroke, and circulatory system disorders and diseases. 
Povišene razine triglicerida, bilo su uzrokovane genetičkom sklonošću ili ishranom bogatom mastima čimbenik su rizika za razvoj bolesti srca, inzult, te
In order to achieve the above said purposes, the invention is a method to form three-dimensional image inside transparent stone (1) comprising process steps of 
PATENTNI ZAHTJEVI Postupak formiranja trodimenzionalne slike unutar transparentnog kamena (1) koji obuhvaća sljedeće korake procesa:
The explosion proof and environment protective gas refueling equipment of Claim 12, characterized in that a plurality of material units are installed as filling material in the inner chamber of gas storage tank, and any two adjacent material units being interconnected. 
Oprema za nadolijevanje plina koja je otporna na eksploziju i štiti okoliš prema zahtjevu 5, naznačena time da je mnoštvo jedinica materijala (1) instalirano kao materijal ispune u unutrašnjoj komori spremnika za plin (A), te su bilo koje dvije susjedne jedinice materijala međusobno povezane.
reacting said compound of Formula I, or salt thereof, with concentrated hydrochloric acid to form a compound of Formula IV or salt thereof; and 
reakciju navedenog spoja s formulom I, ili njegove soli, s koncentriranom klorovodičnom kiselinom da se dobije spoj s formulom IV ili njegova sol; i [image]
In some embodiments, the Form A crystal form remains as the Form A crystal form after application of 2000-psi for about 1 minute. 
Čvrsti oblik prema zahtjevu 1, naznačen time što ostaje kao kristalni oblik Oblika A nakon primjene 2000-psi tijekom oko 1 minute.
The process according to any one of claims 1 to 6, wherein the carboxylic groups of the at least one carboxymethylcellulose are at least partly neutralized by adding to the aqueous mineral pigment material suspension prior or during the grinding step d) one or more polyvalent cations, in situ formed, by adding an acid, preferably H3PO4, or acidic reacting salt such as Na2HPO4, preferably CaHPO4. 
Postupak prema bilo kojem od zahtjeva 1 do 6, gdje su karboksilne skupine barem jedne karboksimetilceluloze barem djelomično neutralizirane tako da se vodenoj suspenziji mineralnog pigmentnog materijala dodaje prije ili za vrijeme koraka usitnjavanja d) jedan ili više polivalentnih kationa, in situ formiranih, putem dodavanja kiseline, poželjno H3PO,, ili kiselo reaktivne soli kao što je Na»HPOy, poželjno CaHPOxy.
is a hydrogen atom, hydroxy, C1-6 alkyl which may be substituted with a hydroxy, C1-6 alkoxy which may be substituted with C1-6 alkoxy, or C1-6 alkylcarbonyl; 
R; je atom vodika, hidroksi, C,g alkil koji može biti supstituiran sa hidroksijem, C,.g alkoksi koji može biti supstituiran sa C1.g alkoksijem, ili Cy.4 alkilkarbonil, ili njihova sol.
After 15min, the reaction mixture was diluted with ethyl acetate. 
Nakon 15 min reakcijska smjesa je razrijeđena sa etil acetatom.
The process according to claim 9, characterized in that the conversion into sevelamer carbonate/bicarbonate with gaseous CO2 is carried out in solid phase. 
Postupak prema patentnom zahtjevu 9, naznačen time, da se pretvorba u sevelamer karbonat/bikarbonat s plinovitim CO; izvodi u krutoj fazi.
wherein: A is a benzene ring, or a pyridine ring, 
A je benzenov prsten, ili piridinov prsten, X je CO, ili CHOH,
The method of claim 3 where the daily dose of the seladelpar or a salt thereof administered to the subject is 50-100 mg, when the dose is calculated as seladelpar. 
Spoj za uporabu u skladu s patentnim zahtjevom 4, naznačen time, da dnevna doza spoja (kada se računa kao slobodna kiselina) iznosi od 50 do 200 mg.
modifying a pair of lengths of track by cutting to correspond to the desired length; 
izmjenu para duljina šina rezanjem kako bi odgovarale željenoj;
The self-tapping screw according to claims 1 to 7, characterized in that said head (215) has a flat underside of the head (220). 
Samonarezni vijak prema zahtjevima 1 do 5, naznačen time da navedena glava (215) ima plosnatu donju stranu glave (220).
The bispecific antibody of Claim 1, wherein there is an intra-chain disulfide bond between cysteine residue 507 of SEQ ID NO: 1 and cysteine residue 707 of SEQ ID NO: 1. 
Bispecifično protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što ima unutarlančanu disulfidnu vezu između cisteinskog ostatka 507 u SEQ ID NO: 1 i cisteinskog ostatka 707 u SEQ ID NO: 1.
CX-REED In some embodiments, the methods of invention furthermore comprises step e), wherein step e) comprises removing at least part of one cation from the AX-REED liquid, while retaining at least 65% of said at least one micro-nutrient in said liquid, wherein said cation is removed through an Cation Exchange Reverse Electro-Enhanced Dialysis (CX-REED) membrane stack, said membrane stack containing 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što postupak nadalje obuhvaća korak e), pri čemu korak e) obuhvaća uklanjanje najmanje dijela jednog kationa 1z tekućine AX-REED uz zadržavanje najmanje 65 % navedene najmanje jedne mikro hranjive tvari u navedenoj tekućini, te se tako dobiva tekućina CX-REED, pri čemu se navedeni kation uklanja putem stoga membrana za kationsku izmjenu reverznom elektro poboljšanom dijalizom,,Cation Exchange Reverse Electro-Enhanced Dialysis" (CX-REED), te navedeni stog membrana sadrži i)
✔ a third articulated telescopic segment (11) actuated by a third hydraulic cylinder (12) attached to the second articulated telescopic segment (9); 
Y treći hidraulični cilindar (12), pričvršćen na drugi uzglobljeni teleskopski segment (9), aktuira treći uzglobljeni teleskopski segment (11);
A polypeptide for use as a medicament for regenerating nerve fibers in a subject that exhibits an impaired sensory neural response, wherein the polypeptide comprises an amino acid sequence that is at least 80% identical to amino acids 15-113 of SEQ ID NO:1, and wherein the polypeptide, when dimerized, binds to a complex containing GFRa3 and RET. 
Polipeptid za uporabu u vidu lijeka za regeneriranje živčanih vlakana kod subjekta koji ispoljava narušen senzorni živčani odgovor, naznačen time, što polipeptid sadrži aminokiselinsku sekvencu koja je najmanje 80% identična sa amino.kiselinama 15-113 SEQ ID NO:1, 1 gdje se polipeptid, kada se dimerizira, vezuje u kompleks koji sadrži GFR93 i RET.
In the following example, the method according to this invention is described in more detail, this example being for illustration only, without limiting in any way the scope of the invention which is unequivocally defined by the patent claims and the description part. 
U sljedećem primjeru postupak prema ovom izumu je opisan detaljnije, gdje ovaj primjer služi samo kao ilustracija, a nikako kao ograničenje opsega zaštite ovog izuma, kojeg nedvosmisleno definiraju Patentni zahtjevi i Opis izuma.
Isomer A, which is believed to have the 2 R,3 R,11b S configuration (the absolute stereochemistry was not determined), was characterized by 1H-NMR, 13C-NMR. IR, mass spectrometry, chiral HPLC and ORD. 
Izomer A, za kojeg se smatra da ima 2R,3R,11bS konfiguraciju (apsolutna stereokemija nije određena), je okarakteriziran pomoću 'H-NMR, '*C-NMR, IR, masene spektrometrije, hiralne HPLC i ORD.
The sewn ball, as recited in any one of claims 1 to 6, wherein the sewn ball is a sewn football or a sewn volleyball, or wherein the housing (4) comprises 6-32 leather pieces. 
Zašivena lopta prema bilo kojem od zahtjeva 1 do 4, naznačena time, da se kod zašivene lopte radi o zašivenoj lopti za nogomet ili za rukomet, ili time da se vanjski omotač (4) sastoji od 6 do 32 kožna komada.
The method of claim 4, wherein said humanized antibody comprises a variable heavy chain region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3 having the sequences of SEQ ID NO: 117, SEQ ID NO: 123, and SEQ ID NO: 135, respectively; and wherein said antibody comprises a variable light chain region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3 having the sequences of SEQ ID NO: 99, SEQ ID NO: 104, and SEQ ID NO: 115, respectively. An anti-IL-13 antibody that binds specifically to human IL-13, wherein said antibody is obtainable by the method of any one of claims 1 to 7. The anti-IL-13 antibody of claim 8, wherein said anti-IL-13 antibody comprises the amino acid sequence of the antibody produced by hybridoma 228B/C-1 (PTA-5657). 
Farmaceutski pripravak koji sadrži antagonističko anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen koji se specifično veže na ljudski IL13 i fiziološki prihvatljiv nosač, naznačen time što navedeno anti-ljudsko IL13 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži regije koje određuju komplementarnost CDRH1, CDRH2 i CDRH3 koje imaju aminokiselinske sekvence od SEQ ID NO: 117, SEQ ID NO: 123, i SEQ ID NO: 135, odnosno, i varijabilnu regiju lakog lanca koja sadrži regije koje određuju komplementarnost CDRL1, CDRL2 i CDRL3 koji imaju aminokiselinske sekvence od SEQ ID NO: 99, SEQ ID NO: 104, i SEQ ID NO: 115, odnosno, i pri čemu je navedeno anti-ljudsko IL13 antitijelo ili njegov funkcionalni fragment formulirano da se daje intravenski, intraperitonealno, intramuskularno, subkutano ili oralno.
Accordingly, the present invention provides methods for treating a disorder involving cells expressing CD38 as described above, which methods comprise administration of a CD38BP of the present invention combined with one or more additional therapeutic agents as described below. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema bilo kojem zahtjevu od 18 do 21, naznačen time, što se postupak sastoji od primjene jednog ili više dodatnih terapeutskih sredstava kod bolesnika.
An aqueous pharmaceutical formulation comprising insulin glargine in a concentration of 200-650 U/mL of insulin glargine being equimolar to 200-650 IU human insulin, wherein the pH is between 3.4 and 4.6, for use in providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient. 
Vodeni farmaceutski pripravak sa pH između 3.4 1 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa IL, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
A method according to any of numbered embodiments 1 to 10, wherein the temperature of the surface of the periphery of the first rotor is at least 100 °C higher than the temperature of the surface of the periphery of the fourth rotor. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 10, pri čemu je površinska temperatura periferije prvog rotora najmanje 100C viša od temperature površinske temperature periferije četvrtog rotora.